TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04939779
Drug: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05974007
Drug: Neoadjuvant immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery
Study: NCT04749563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of IGC AD1 oral Solution
Study: NCT05940441
Drug: Capecitabine 500Mg Oral Tablet
Normalized name: Capecitabine 500mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg/m² body surface area twice daily for 1 year
Study: NCT06216197
Drug: DEX group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).
Study: NCT05754801
Drug: Yunzhi Essence
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yunzhi Essence capsule
Study: NCT05180708
Drug: QTORIN 3.9% rapamycin anhydrous gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: QTORIN 3.9% rapamycin anhydrous gel
Study: NCT05180708
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle (QTORIN anyhydrous gel)
Study: NCT05157711
Drug: Anusol
Normalized name: ANUSOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily at night and in the morning and after each bowel movement for two weeks
Study: NCT05157711
Drug: Relief [Name]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily at night and in the morning and after each bowel movement for two weeks
Study: NCT05157711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily at night and in the morning and after each bowel movement for two weeks
Study: NCT00914004
Drug: Desipramine HCl 50 mg Tablets Cord Laboratories
Normalized name: desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05182567
Drug: GLS-5310 (Group 1)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS-5310 DNA plasmid vaccine
Study: NCT05182567
Drug: GLS-5310 (Group 2)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS-5310 DNA plasmid vaccine
Study: NCT05182567
Drug: GLS-5310 (Group 3)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS-5310 DNA plasmid vaccine
Study: NCT05182567
Drug: GLS-5310 (Group 4)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS-5310 DNA plasmid vaccine
Study: NCT04797312
Drug: Opioid Free Anaesthesia protocol
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: The OFA protocol begins with a systematic preoperative premedication with clonidine, continues with an adapted intraoperative management without opioid administration, but associating several molecules (clonidine, magnesium, lidocaine, ketamine) and ends with a continued administration of xylocaine up to 1 hour postoperatively in PACU. The use of an opioid in preoperative or intraoperative phases is considered as a deviation from the protocol.~To these different molecules, the use of hypnotic molecules left to the choice of the practitioner and a curare will be systematically associated.
Study: NCT04682808
Drug: FCN-338
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-338 will be given orally in ascending doses starting at 50 mg QD until the maximum tolerated dose or recommended dose is reached.
Study: NCT04879992
Drug: Tetracycline,Metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT05265286
Drug: FRSW117
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects of high dose group are being received four doses(50 IU/kg,once a week or every 7 days) of FRSW117.~Subjects of low dose group (40 IU/kg,once a week or every 7 days)are being received four doses of FRSW117.
Study: NCT04842331
Drug: Standard of Care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive institutional SOC for the treatment.
Study: NCT04790903
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive Cyclophosphamide at a dose of 750 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
Study: NCT04790903
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Doxorubicin at a dose of 50 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
Study: NCT00000971
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05480241
Drug: Pancreatic Enzyme Replacement Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
Study: NCT05480241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Omeprazole 20mg once daily on fasting
Study: NCT05265338
Drug: KC1036
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg QD
Study: NCT04656288
Drug: BI 764198 - Formula B
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 764198
Study: NCT05117593
Drug: FBL-MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBL-MTX is available as sterile liposomal dispersion for injection at nominal dose strength of 1 mg/mL of methotrexate free base. The dose of 0.1 mg was selected as starting dose in the present study. Three subsequent FBL-MTX dose levels are pre-planned: 0.33 mg, 1 mg and 2.5 mg.
Study: NCT05117593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will consist of sterile saline 0.9% NaCl solution.
Study: NCT05670808
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Different doses on epinephrine will be administered to study arms to observe its impact on blood loss
Study: NCT03613181
Drug: Physician's Best Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator: one of 3 pre-determined choices of therapies: capecitabine or eribulin or high-dose IV methotrexate.
Study: NCT04776629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for orticumab, containing all components of formulation except the active ingredient
Study: NCT04487613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule
Study: NCT04982575
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Study: NCT04982575
Drug: Placebo (cagrilintide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Study: NCT05430243
Drug: Diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: diuretics as clinically indicated
Study: NCT06238011
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline total volume50 ml prepared by nurse anesthetist at preprocedure room, start Normal Saline by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass. Record patients data by nurse anesthetist
Study: NCT05362188
Drug: Nicotinamide Topical
Normalized name: nicotinamide topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with discoid lupus erythematosus (face \& scalp) will be given topical nicotinamide in two concentrations (2\&4%) to apply twice daily for 12 consecutive weeks and then follow up.~Topical nicotinamide will be prepared in different forms (cream \& gel).
Study: NCT05339373
Drug: Airtal® film-coated tablet 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Airtal ® is manufactured by Gedeon Richter- RUS, Russia / Gedeon Richter, Hungary. Each tablet contains 100 mg of aceclofenac.
Study: NCT06229067
Drug: Cyclophosphamide (tablet)
Normalized name: cyclophosphamide Oral Tablet
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic oral cyclophosphamide 50 mg daily. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT06229067
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic oral capecitabine 500 mg three times daily. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT06555575
Drug: Ubiquinone 200 Mg Oral Capsule
Normalized name: ubiquinone 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: By mouth three times daily for three months
Study: NCT06183736
Drug: CVL237 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
Study: NCT05782933
Drug: Modified Ponticelli regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid and cyclophosphamide
Study: NCT04578873
Drug: QPX7831
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT04578873
Drug: placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral matched placebo capsule
Study: NCT04872686
Drug: 0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of participants 768 COVID-19 positive, moderately ill admitted patient who will receive intervention~Step 1: Enrollment of the study populations by applying inclusion and exclusion criteria Step 2: Randomization to allocate experimental and controlled group by using table of random number Step 3: Application of 0.6% PVP-I spray to experimental group and distilled water to control group Step 4: Follow up (waiting for 2-5 minutes) Step 5: Collection of nasopharyngeal and oropharyngealsawab for RT-PCR test for both group Step 6: Observation of the patients for 30 minutes for possible early adverse effects (if any) and subsequent management (if needed).~Step 7: Analysis data collection, data processing and analysis by using SPSS software.
Study: NCT04872686
Drug: 0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of participants 20 asymptomatic to mild COVID -19 patients having multiple comorbidity who will receive intervention~Step 1: Selection of 20 patients randomly with no or mild symptoms and obtain their consent for the further tests.~Step 2: Collection of 2nd, 3rd and 4th sample from nasopharynx and oropharynx hourly Step 3: Data collection, data processing and analysis by using SPSS software
Study: NCT04872686
Drug: 0.6% PVP-I Oral and nasal spray to healthy volunteer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of participants 10 healthy individual who accept intervention 0.6% PVP-I oronasal spray~Step 1: Selection of 10 healthy volunteers randomly who will be selected for using 0.6% PVP-I Oro-Nasal spray 2 puff inside both nostrils and mouth 3 to 4 times a day for one month.~Step 2: Collection of blood \& urine of participants on day 0, 10, 20, 30 for determination of any change in biochemical marker (thyroid, kidney and liver functions will be done) Step 3: Data collection, data processing and analysis by using SPSS software
Study: NCT05256108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner
Study: NCT05523102
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketorolac/NSAID
Study: NCT05402189
Drug: Ketodex, Fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be randomized into 2 groups : group (KD) and group (OP) . Two 20 ml syringes, labelled loading and another two 20 ml syringes labelled maintenance will be given to each patient according to his group.~Group (KD): patients will receive 1mg/kg ketamine and 1ug/kg dexmiditomidine in their respective loading syringes diluted in 20ml normal saline. Then , they will receive ketamine 0.1 mg/kg /hr and dexmedetomidine0.2ug/kg/hr in their maintenance syringes prepared in 20 ml normal saline in a concentration of 1mg/ml ketamine and 1ug/ml dexmiditomidine respectively .~Group (OP): one of the loading syringes will contain fentanyl in a dose of 2ug/kg diluted in 20 ml normal saline and the other loading syringe will contain normal saline. Then, the patients will receive 0.5ug/kg/hr fentanyl through one of the maintenance syringes while the other syringe contains normal saline.
Study: NCT05325177
Drug: High Dose Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (20-10-10 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
Study: NCT05147415
Drug: Tesomet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination
Study: NCT05264038
Drug: OC514 (Mid dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid dose level of OC514
Study: NCT06549842
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention for this study is the dose of heparin. Patients randomized to group 1 will receive a heparin dose of 50U/kg and those in group 2 will receive a lower dose of heparin at 25U/kg. Recovery period for group 1 would be 2 hours whereas for group 2 would be 1 hour.
Study: NCT06040515
Drug: Probiotic Formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule with 25 billion live strains of Escherichia coli Nissle 1917
Study: NCT04864067
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Consolidation Chemotherapy
Study: NCT04864067
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Consolidation Chemotherapy
Study: NCT05707273
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05244057
Drug: Placebo of Hepalatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c., qd for 48 weeks
Study: NCT04280692
Drug: Artemether lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three day curative regimen 20mg/120mg
Study: NCT06465862
Drug: Biktarvy Pill
Normalized name: Biktarvy Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biktarvy prescribed with TruTag system and tagged with TruTag microparticles.
Study: NCT06058546
Drug: Jiuweihuaban Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiuweihuaban pill placebo 1 bag(12 g placebo per bag),p.o.,tid,for 12weeks.
Study: NCT05029037
Drug: High doses of intravenous vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two (2) High doses of intravenous vitamin C for seven (7) days.
Study: NCT06525350
Drug: HB1801 (docetaxel, albumin-bound）
Approvals — FDA: no, EMA: no, PMDA: no
Description: An improved new formulations of docetaxel
Study: NCT04447898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
Study: NCT04565145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given three placebo capsules per day for one week
Study: NCT01451450
Drug: QGE031
Approvals — FDA: no, EMA: no, PMDA: no
Description: QGE031 liquid for subcutaneous injection.
Study: NCT01451450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liquid for subcutaneous injection.
Study: NCT05522309
Drug: ET0111
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with ET0111 administered, once daily (QD).
Study: NCT05587322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally via tablet
Study: NCT06008652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05005507
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF film-coated tablet will be administered orally once daily.
Study: NCT05511870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Study: NCT05801705
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor includes Arimidex, Aromasin, Femara.
Study: NCT04899180
Drug: 99mTc-PYP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioisotope used by SPECT/CT imaging
Study: NCT05364866
Drug: Antiarrhythmic drug Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone, Sotalol and Amiodarone
Study: NCT05079672
Drug: 0,9% Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0,9% will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by- pass.
Study: NCT05395117
Drug: AZD5462
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Arm A: Participants will receive the IMP, AZD5462 Dose A starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin~Treatment Arm B: Participants will receive the IMP, AZD5462 Dose B starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin
Study: NCT05395117
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive rosuvastatin as a single dose administered with digoxin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
Study: NCT05951413
Drug: estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estradiol in form of Cycloprogynova white pills starting dose is one pill t.i.d may be increased to two pills t.i.d according to endometrial thickness in day 9 measured by vaginal ultrasound.
Study: NCT05164770
Drug: R-CHOP; R-DA-EPOCH; R-HD MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg/m2 d1, Doxorubicin 50mg/m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg/m2 or Vindesine 3mg/m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/m2, Epirubicin 15mg/m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.
Study: NCT04528667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT05148325
Drug: BAT4706
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration cycle was proposed to be 3 weeks (Q3W), i.e., 21 days in a cycle, and the first 4 cycles were administered on the first day of each cycle.
Study: NCT05098522
Drug: IRL201104
Approvals — FDA: no, EMA: no, PMDA: no
Description: lyophilised powder for reconstitution for IV dosing
Study: NCT05098522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for IRL201104
Study: NCT06323681
Drug: Peginterferon α-2b based treatment group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon α-2b injection, 180mcg, s.c, once a week, for 48 weeks. If the baseline HBV DNA is higher than the minimum detection limit (using high-sensitivity kit), combined with nucleos(t)ide analogs (NAs) is recommended.
Study: NCT06323681
Drug: NAs monotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally, for 48 weeks.
Study: NCT05061693
Drug: INCB054707
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Tablet
Study: NCT05061693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Tablet
Study: NCT04605978
Drug: S95011 concentrate for solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
Study: NCT05339633
Drug: [14C]-D-0502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: \[14C\]-D-0502 and D-0502
Study: NCT05791097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions will consist of a sterile, normal saline solution. Placebo will be administered on Day 1 of each 21-day cycle
Study: NCT04717752
Drug: Troprilin
Approvals — FDA: no, EMA: no, PMDA: no
Description: triptorelin acetate injection
Study: NCT04605978
Drug: Placebo concentrate for solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
Study: NCT02511418
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04927780
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT04927780
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV